HIGHLIGHTS
- who: Ian R. White and colleagues from the Medicine, Columbia University, New York, New York, United States of America, Department of Molecular have published the article: A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population, in the Journal: PLOS ONE of 11/Dec/2020
- what: Variability in CZP efficacy remains a problem for clinicians thus the aim of this study was to identify genetic variants predictive of CZP response. The authors report the first genomewide study of a North American cohort of RA patients with moderate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.